SUMMARY The efficacy of cimetidine in the prevention of gastrointestinal haemorrhage in a general intensive care unit was evaluated in 221 patients by a placebo controlled double blind randomised study. Criteria for bleeding were (i) haematemesis or gastric aspirate >50ml fresh blood, (ii) melaena or fresh blood per rectum with an upper source verified by endoscopy if the gastric aspirate was clear, (iii) a fall in haemoglobin level >2 g/dl in a 24 hour period associated with either 4+ occult blood in stools, or coffee ground gastric drainage of at least 100 ml. The drug and placebo groups were similar for age, sex, duration of study and risk factors. One hundred and fourteen received cimetidine and 107 placebo. Only 8% of the patients bled with no significant difference between the two groups (6/114 cimetidine, 11/107 placebo; p=016). There was no correlation between the frequency of bleeding and either the number of risk factors per patient or the duration of intensive care unit stay. Thirteen patients died in each study group, resulting in overall mortality of 12%. The low incidence of haemorrhage, the lack of statistical benefit from cimetidine and the similar mortality all argue against the routine use of this drug in intensive care unit patients.
Acute gastrointestinal haemorrhage from stress ulceration can be a serious and life threatening complication in critically ill patients.lA Gastric acid must be present for stress ulcers to occur;5 6 on this basis H2-receptor antagonists such as cimetidine have been tried with the specific aim of reducing the incidence of haemorrhage in these critically ill, high risk patients. A number of prospective controlled studies comparing cimetidine with placebo has produced conflicting results,7-11 and in most only a small number of patients was assessed. We therefore undertoook a large prospective randomised, double blind study to determine whether cimetidine administered prophylactically could lower the incidence of bleeding in a general medical-surgical intensive care unit.
Methods

PATIENTS
The study was conducted prospectively over a 21 month period in the Kingston General Hospital's medical-surgical intensive care unit. Of a total of 1116 admissions, 378 patients were ineligible because of previously determined exclusions. These included bleeding on admission to the intensive care unit, pregnancy, renal failure requiring haemodialysis or peritoneal dialysis, drug overdosage, acute myocardial infarction, and the use of antacids. Two hundred and seven additional patients were excluded because their stay in the unit was less than 24 hours. Of the remaining 531 eligible patients 221 completed the trial (41%). The remainder were excluded because of inability to obtain early consent, refusal to enter the study, death within the first 24 hours, accidental omission by house staff, and miscellaneous reasons (Table 1) .
Patients were randomised in a double blind method to receive injections of either cimetidine 300 mg in 20 ml normal saline or placebo prepared in an identical manner, each given intravenously every six hours. Antacids were not administered to any patient.
The study was terminated when either bleeding occurred or the patient was discharged from the unit. Bleeding was defined by the following strin- each group, resulting in an overall mortality of 12%. None of the deaths in either group was directly due to bleeding. The duration of bleeding in the cimetidine group ranged from one to six days with a mean of 3-0 days and in the placebo group from one to nine days with a mean of 2-9 days. The bleeding was only mild in most cases. The volume of packed cells administered to the cimetidine group ranged from 0 to 900 ml with a mean of 600 ml and in the placebo group from 0 to 1200 ml with a mean of 550 ml. Bleeding did not lead to haemodynamic instability in any of the patients and was not a contributing factor to the death of the one patient who died in the cimetidine group or of the three who died in the placebo group. Eight major risk factors were analysed for each patient: major operative procedure, respiratory failure, sepsis, shock, trauma, coma, renal failure and jaundice. The percentage of patients with each risk factor is shown in Figure 1 . With the exception of sepsis, there was a close similarity between the two groups. Cumulative risk factors for each individual were analysed; Figure 2 shows the number of patients in each group with one, two, and three-six risk factors. The mean number of risk factors was two per patient in both study groups. There was no correlation between the occurrence of haemorrhage and the number of risk factors in either the cimetidine or the placebo groups. Tables 3 and 4 tabulate the primary diagnosis and the associated risk factors for each patient who bled.
The relationship between the occurrence of haemorrhage and the duration of study was analysed for each group (Figure 3 ). Seventy per cent of patients were in the study for 1-3 days, and during The incidence of bleeding in the control group was 10%, somewhat lower than the mean rate (20%) found in comparable prospective double blind studies.
Our figure compares favourably with the 14% incidence found by Bassolu and in a recent prospective evaluation by Schuster et al. 15 The reasons for the lower incidence remain unclear.
It cannot be ascribed to a difference in the severity of illness in the drug and placebo groups as the number of patients with each risk factor was similar in each group. Moreover the severity of illness in Groll, Simon, Wigle, Taguchi, Todd, and Depew our study based on the distribution of risk factors is comparable with other studies.3 10 14 Use of antacids was not responsible for the low incidence as none of our patients received antacids. Possibly our strict criteria for defining haemorrhage may have contributed to the lower bleeding rate.
Our results may not necessarily apply to critically ill patients in other intensive care unit settings. For example, burn patients' 16 who have a high incidence of stress ulceration are not nursed in our general medical-surgical intensive care unit. It could also be argued that the number of excluded patients may have influenced the outcome. Only 20% of all patients admitted to the unit were entered into the study. The number of excluded patients reflects the difficulties encountered in establishing clinical protocols in critically ill patients. Many patients did not meet the study criteria, or had already been started on antacids or cimetidine before admission to the intensive care unit. For some permission for entry into the study was denied and several patients were not randomised on admission to the intensive care unit. Nevertheless our figures compare very favourably with other intensive care unit studies3 0 14 with regard to the number of patients entering the study as well as to the distribution of risk factors. As a formal demographic comparison of excluded and included patients was not done, our conclusions cannot be extended to the excluded patients whose characteristics may have differed from those of the study group.
In contrast with previous studies,3 14we found no correlation between the number of risk factors per patient and the risk of bleeding -bleeding occurred equally frequently in the presence of one, two, or more risk factors. Neither did the duration of intensive care unit stay correlate with the frequency of bleeding, as the large majority of haemorrhages occurred during the first 72 hours. This observation suggests that bleeding would not have been much more common had we studied a larger group of patients whose stay was longer than 72 hours. This is the largest prospective double blind study comparing cimetidine with placebo for the prevention of gastrointestinal haemorrhage in an intensive care unit population. Most other prospective studies have compared cimetidine with antacids and some did not include a placebo group. There are three clinical trials showing the superiority of cimetidine over placebo. Basso bleeding. In another controlled trial cimetidine was significantly superior to placebo in 50 patients with fulminant hepatitis.8 In contrast, however, Zinner and coworkers7 could find no difference between cimetidine and placebo, whereas antacids appeared to be efficacious in the prevention of haemorrhage. Friedman and coworkers9 studied 36 of 150 patients requiring mechanical ventilation and could show no significant difference between cimetidine and placebo, while in a large study comparing antacids with cimetidine Priebe and coworkers14 established antacids to be superior to cimetidine in the prevention of haemorrhage; neither treatment was compared with placebo. In another study by the same investigators,13 antacids were found to be superior to a control group who received no specific form of treatment. The incidence of bleeding (25%) was the same in the cimetidine treated patients (versus antacids) and in the control group (versus antacids).
These findings suggest that cimetidine may be no better than placebo in the prevention of haemorrhage in that particular intensive care unit population.
The objective of our study was to determine the efficacy of cimetidine in preventing haemorrhage, not to establish the incidence of stress ulceration which commonly occurs in intensive care unit populations. We therefore deliberately did not routinely include an endoscopic evaluation but reserved it for those patients in whom bleeding warranted such investigation. The low incidence of haemorrhage In this study suggests either that stress ulceration is uncommon in such a setting or that only a small proportion of patients with ulceration bleed. Other studies suggest that the latter is much more likely than the former.1 5 16 In either case the outcome of our study suggests that cimetidine should not be prescribed prophylactically to all patients entering a general medical-surgical intensive care unit. The low incidence and mild extent of the haemorrhage, the lack of statistical benefit from cimetidine and the similar mortality in the two study groups all argue against the routine use of this agent.
In other studies,13 14 17 18 however, the incidence of haemorrhage in critically ill patients has been significantly reduced by the hourly antacid titration of gastric juice to a pH greater than 3-5. Thus antacids may be superior to cimetidine as prophylaxis against bleeding from stress ulceration.
We are indebted to Ruth Pattenden for supervising the study and to the physicians and nurses of the Kingston General Hospital Intensive Care Unit for their cooperation and support. This project was supported by Smith Kline and French Canada Ltd.
